A Look At Inventiva (ENXTPA:IVA) Valuation As NATiV3 Enrollment Completes And Odiparcil Rights Are Sold

NodeGuardian · 2026-04-08T05:16:19+00:00

Inventiva has completed enrollment for its NATiV3 trial for lanifibranor, attracting investor interest. Despite earnings volatility, the stock shows significant returns and is considered undervalued due to the potential of lanifibranor for MASH treatment in the US.

NodeGuardian

2026-04-08 05:16:19

Abstract generation in progress

Inventiva (ENXTPA:IVA) has completed enrollment for its NATiV3 trial for lanifibranor in MASH and sold odiparcil rights, leading to increased investor attention. Despite recent earnings volatility, the stock has seen significant returns, with analysts setting targets much higher than its current share price. The narrative analysis suggests a substantial undervaluation, primarily due to the anticipated success of lanifibranor as a potential second oral drug for MASH in the US, despite the company’s current losses.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.